Kura Oncology Posts $0.92/Share Q4 Loss as KOMZIFTI Launch Delivers $2.1M in Initial Revenue
Kura Oncology reports wider Q4 loss of $0.92/share as KOMZIFTI launch generates $2.1M in first weeks; payers implement step edits favoring drug over competitor.